Description

Since 2020 EASL Studio has been a part of the International Liver Congress (ILC), bringing you the most up-to-date research live from the congress. But EASL Studio is evolving.

EASL Studio is now a new platform through which we will be exploring hepatology every week, from every angle. Through live debates, interviews, and roundtable discussions, EASL Studio will be a chance to peak behind the scenes. Hear the expert’s opinion on the latest research. Discover what it’s like to be a young investigator. Meet the Nurses, the allied health professionals, and the patients they work with.

Watch on-demand the first Session that was broadcasted on Wednesday 27 October 2021.

 

Time Title
00:00-04:12

Welcome and Introductions

Thomas Berg, University Clinic Leipzig, Germany

Maria Buti, Valle Hebron University, Spain

04:12-28:26

Topic 1: Raising awareness about Liver Cancer

Nathalie Ganne-Carrié, Avicenne Hospital, France

Peter Jepsen, University of Aarhus, Denmark

28:26-47:34

Topic 2: Liver Cancer Summit: Highlights from 2021 and what awaits us in 2022

Angela Lamarca, University of Manchester, United Kingdom

Jean-Charles Nault, Avicenne Hospital, France

47:34-50:31

Closing remarks

Thomas Berg, University Clinic Leipzig, Germany

Maria Buti, Valle Hebron University, Spain

 

Moderators

 
Thomas Berg Professor Dr Thomas Berg is Head of the Division of Hepatology, Department of Medicine II, at the Leipzig University Medical Center, Germany, and Chair of the University Liver Tumor Center, and Vice-Chair of the University Liver Transplant Center Leipzig. He is Secretary General of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019. He has published more than 440 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 76 (Scopus).
Maria Buti Maria Buti is EU Policy Councillor from January 2020. She is a Professor of Medicine and Chief of the Internal Medicine and Hepatology Department at Hospital General Universitari Valle Hebron, Barcelona. Professor Buti’s main area of interest and expertise is viral hepatitis with particular experience in diagnosis and therapy of hepatitis B and C.

 

Faculty

 
Nathalie Ganne Carrié Nathalie Ganne-Carrié, is MD PhD and Professor in Hepatology. Since 2014, she has headed the liver unit of the Hôpitaux Universitaires Paris Seine Saint-Denis, France, in which more than 50% of the activity is dedicated to Primary liver tumour. She holds her PhD degree in oncology, studying hepatocellular carcinoma using local resources and French national cohorts (CIRRAL, CirVir, HEPATHER). She also works closely with several teams to further translational research. Since 2019, she has been the general secretary of AFEF, the French Society of Hepatology.
Peter Jepsen Peter Jepsen is a Consultant Hepatologist and Clinical Professor of Hepato-Epidemiology at Aarhus University Hospital in Aarhus, Denmark. Professor Jepsen’s primary interests are alcohol-related liver disease and hepatocellular carcinoma, most notably the value of surveillance for hepatocellular carcinoma among patients with alcohol-related cirrhosis. He has published more than 100 articles in international peer-reviewed journals, most of them in the field of hepato-epidemiology.
Angela Lamarca Dr Angela Lamarca (MD, PhD, MSc) is a Consultant in Medical Oncology at The Christie NHS Foundation Trust, specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group, ENETS Advisory board and a faculty member of the ESMO Non-Colorectal Gastrointestinal Cancer group.
Jean-Charles Nault Jean-Charles Nault received is MD and PhD from Paris Descartes University. He is currently professor in the liver unit of the Avicenne Hospital in Bobigny, France with a high priority on early detection of primary liver tumors and on therapeutic innovation. He is also an active member of the laboratory of “functional genomics of solid tumors” at the INSERM UMR 1138 in Cordeliers Research Center. His research is dedicated to translational research, in particular the identification of new driver genes in hepatocellular adenoma and hepatocellular carcinoma, of new therapeutic targets and of the molecular determinants of hepatocellular carcinoma’s prognosis.